BASEL (Reuters) - Drugmaker Roche faces a double whammy in 2011 as demand for best-selling Avastin cancer drug slows and U.S. healthcare reforms combined with a drive by European governments to cut drugs bills eats into its profit.
BASEL (Reuters) - Drugmaker Roche faces a double whammy in 2011 as demand for best-selling Avastin cancer drug slows and U.S. healthcare reforms combined with a drive by European governments to cut drugs bills eats into its profit.
